PHAIT aims to intercept lung cancer, the deadliest cancer worldwide, by treating pre-cancer dysplasia with oral Iloprost to reduce lung cancer incidence and death. Iloprost is an immuno-modulator repurposed drug that is currently FDA approved, reimbursed, and routinely used for the treatment of pulmonary arterial hypertension (PAH) and Raynaud’s disease. Consequently, Iloprost is de-risked with proven patient safety and tolerance. Daily doses of a proprietary formulation of oral Iloprost, exclusively licensed from Bayer to be manufactured by PHAIT, will provide the therapeutic breakthrough. Oral Iloprost has demonstrated effectiveness in a published Phase 2a clinical study where patients taking the drug for six months responded significantly with precancerous dysplasia reduced by half: https://aacrjournals.org/cancerpreventionresearch/article/4/6/793/49855/Oral-Iloprost-Improves-Endobronchial-Dysplasia-in?searchresult=1.
Company Details
- Founded
- 2020
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- https://phait.com/
- Keywords
- Boulder.
Phait, Inc. Questions
Phait, Inc.'s website is https://phait.com/
Phait, Inc.'s LinkedIn profile is https://www.linkedin.com/company/phait-inc
Phait, Inc.'s industry is
Pharmaceutical Manufacturing
Phait, Inc.'s top competitors are
Limber Prosthetics, Inc.,
Ibos.cloud,
Bevboost,
Keiretsu Forum Spain,
Tigerblocks,
Tybr Health,
Mabi Artisanal Tea,
Climate Tech Venture Review,
Seneca Therapeutics, Inc.,
Lahjavida.
Phait, Inc.'s categories are Pharmaceutical Manufacturing
Phait, Inc.'s founding year is 2020
